Viridian Therapeutics (VRDN) Price & Analysis

Compare

1,388 Followers

VRDN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$9.90 - $27.20

Previous CloseN/A

Volume201.32K

Average Volume (3M)752.25K

Market Cap

$1.70B

Enterprise Value$789.25M

Total Cash (Recent Filing)$563.36M

Total Debt (Recent Filing)$21.34M

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Nov 18, 2025

EPS Estimate

-0.95

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.00

Shares Outstanding81,662,370

10 Day Avg. Volume609,043

30 Day Avg. Volume752,251

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.46

Enterprise Value/Revenue2.59K

Enterprise Value/Gross Profit4.34K

Enterprise Value/Ebitda-2.32

Forecast

1Y Price Target

$39.73

Price Target Upside89.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Competitive AdvantageVeli has a competitive advantage to capture the market of chronic thyroid eye disease (TED), or ~80% of TED patients, given its robust efficacy in improving and resolving diplopia in chronic TED.

Market PotentialVRDN-003's SC-administration via a low-volume autoinjector offers game-changing potential for TED, and the readouts of the REVEAL trials could significantly enhance the company's valuation and appeal as an M&A target.

Pipeline ProgressViridian completes enrollment of the pivotal REVEAL Program with VRDN-003, indicating progress in their pipeline.

Bears Say

Regulatory ChallengesExpecting a timely BLA decision and strong launch of veligrotug in the U.S. Viridian remains on track to submit BLA for veligrotug (veli) and apply for priority review.

Viridian Therapeutics News

Viridian Therapeutics completes enrollment in REVEAL-1, REVEAL-2 studies

Viridian Therapeutics (VRDN) announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 clinical trials for VRDN-003...

23d ago

VRDN

Viridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline Outlook

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Viridian Therapeutics. The associated price target...

15d ago

VRDN

Promising Developments and Strategic Advancements Justify Buy Rating for Viridian Therapeutics

BTIG analyst Julian Harrison maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of...

22d ago

VRDN

Positive Outlook for Viridian Therapeutics: Buy Rating Backed by Promising Trial Developments and Strong Financial Position

Serge Belanger, an analyst from Needham, maintained the Buy rating on Viridian Therapeutics. The associated price target remains...

23d ago

VRDN

Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Viridian Therapeutics, retaining the price target of...

23d ago

VRDN

Viridian Therapeutics files automatic mixed securities shelf

07:32 EDT Viridian Therapeutics (VRDN) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

VRDN

Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating

Leerink Partners analyst Thomas Smith maintained a Buy rating on Viridian Therapeutics on August 6 and set a...

2M ago

VRDN

Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm’s price target on Viridian Therapeutics (VRDN) to $32 from $28 and...

2M ago

AMGN

VRDN

Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Viridian Therapeutics and keeping the price target...

2M ago

VRDN

Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo

Wells Fargo lowered the firm’s price target on Viridian Therapeutics (VRDN) to $26 from $27 and keeps an...

2M ago

VRDN

Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments

Viridian Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Derek Archila from...

2M ago

VRDN

Viridian Therapeutics Reports Q2 2025 Financial Results

Viridian Therapeutics, Inc. ( ($VRDN) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

VRDN

Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements

Analyst Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics and decreased the price target to...

2M ago

VRDN

Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics today and set a price target...

2M ago

VRDN

VRDN FAQ

What was Viridian Therapeutics’s price range in the past 12 months?

Viridian Therapeutics lowest stock price was $9.90 and its highest was $27.20 in the past 12 months.

What is Viridian Therapeutics’s market cap?

Viridian Therapeutics’s market cap is $1.70B.

When is Viridian Therapeutics’s upcoming earnings report date?

Viridian Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 41 days.

How were Viridian Therapeutics’s earnings last quarter?

Viridian Therapeutics released its earnings results on Aug 06, 2025. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.009 by $0.009.

Is Viridian Therapeutics overvalued?

According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viridian Therapeutics pay dividends?

Viridian Therapeutics does not currently pay dividends.

What is Viridian Therapeutics’s EPS estimate?

Viridian Therapeutics’s EPS estimate is -0.95.

How many shares outstanding does Viridian Therapeutics have?

Viridian Therapeutics has 81,662,370 shares outstanding.

What happened to Viridian Therapeutics’s price movement after its last earnings report?

Viridian Therapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.009. Following the earnings report the stock price went down -1.376%.

Which hedge fund is a major shareholder of Viridian Therapeutics?

Currently, no hedge funds are holding shares in VRDN

Viridian Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-62.99%

Trailing 12-Months

Asset Growth

-0.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics (VRDN) Earnings & Revenues

Historic Earnings Reports

VRDN Stock 12 Month Forecast

Average Price Target

$39.73

▲(89.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","62":"$62","23.75":"$23.8","36.5":"$36.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,23.75,36.5,49.25,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,22.36,25.58,28.8,32.019999999999996,35.239999999999995,38.46,41.68,44.9,48.12,51.339999999999996,54.559999999999995,57.78,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,20.723846153846154,22.307692307692307,23.89153846153846,25.475384615384613,27.059230769230766,28.643076923076922,30.226923076923075,31.81076923076923,33.39461538461538,34.97846153846153,36.562307692307684,38.146153846153844,{"y":39.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,19.66769230769231,20.195384615384615,20.723076923076924,21.25076923076923,21.77846153846154,22.306153846153848,22.833846153846153,23.361538461538462,23.88923076923077,24.416923076923077,24.944615384615386,25.472307692307695,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >